Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: The PREMIER trial demonstrated the superiority of initial adalimumab (ADA)+MTX vs the individual monotherapies in MTX-naïve patients (pts) with early, aggressive rheumatoid arthritis (RA). The purpose of this study was to assess long-term outcomes in pts treated with ADA, with or without MTX, for up to 10 years (yrs).
Methods: Pts completing the 2yr blinded study were eligible to receive open-label (OL) ADA for up to an additional 8 yrs; MTX could be added at the investigator’s discretion. This post hocanalysis evaluated data as observed (ie, no imputation for missing data); results are summarized overall and by initial treatment arm. DAS28(CRP) and HAQ-DI were used to assess clinical and functional outcomes, respectively. Radiographic progression (change from baseline in mTSS) was assessed in 10yr completers with radiographic data available at baseline and yr 10. Adverse events (E) of interest were summarized for pts receiving ≥1 ADA dose and presented as E/100-pt yrs (PY).
Results: Of the 799 pts randomized, 497 (62%) entered the OL extension; 250 (31%) maintained OL ADA±MTX through yr 10. MTX co-therapy was (re)initiated in 261 pts (53%) during the OL extension. Overall, pts completing 10 yrs of therapy continued to demonstrate effective disease control (mean DAS28=2.4; mean HAQ-DI=0.6; mean ΔmTSS=7.8). Although the addition of OL ADA±MTX to the initial MTX and ADA arms at yr 2 led to increases in the proportions achieving DAS28(CRP) <2.6 and HAQ-DI <0.5 over time, differences between initial treatment arms persisted through yr 10 (Table). Further, ΔmTSS remained significantly lower over time in the initial ADA+MTX arm compared with the 2 monotherapy arms (ΔmTSS =4.0, 11.0, and 8.8 at yr 10 for the initial ADA+MTX, MTX, and ADA arms, respectively; both P <0.05), despite OL ADA±MTX slowing progression comparably in each of the arms (both P>0.05). No new safety signals arose following 3708 PY of ADA exposure (N=697 pts): serious infections =2.6 E/100-PY; TB =0.2 E/100-PY; malignancy (other than NMSC) SIR (95% CI) =0.89 (0.62, 1.26). There were 23 deaths during this 10yr study, resulting in an SMR (95% CI) of 0.72 (0.49, 1.02).
|
|
ADA+MTX → |
MTX → |
ADA → |
|
Parameter |
OL ADA±MTX |
OL ADA±MTX |
OL ADA±MTX |
|
DAS28(CRP) <2.6, n/N (%) |
|
|
|
|
Yr 2a |
131/198 (66) |
64/167 (38) |
69/160 (43) |
|
Yr 10 |
59/78 (76) |
41/73 (56) |
50/81 (62) |
|
HAQ-DI <0.5, n/N (%) |
|
|
|
|
Yr 2a |
130/199 (65) |
88/167 (53) |
74/160 (46) |
|
Yr 10 |
54/85 (64) |
42/77 (55) |
45/85 (53) |
|
ΔmTSS ≤0.5, n/N (%) |
|
|
|
|
Yr 2a |
61/85 (72) |
33/77 (43) |
39/84 (46) |
|
Yr 10 |
31/86 (36) |
24/77 (31) |
22/85 (26) |
|
DAS28(CRP) <2.6 + HAQ-DI <0.5 + ΔmTSS ≤0.5b, n/N (%) |
|
|
|
|
Yr 2a |
29/85 (34) |
10/77 (13) |
12/84 (14) |
|
Yr 10 |
17/86 (20) |
5/77 (7) |
6/85 (7) |
|
aEnd of double-blind period. |
|||
|
bNRI was used to replace missing DAS28(CRP) or HAQ-DI values. |
|||
Conclusion: ADA±MTX maintained effective disease control for up to 10 yrs in pts with early, aggressive RA. Of the pts who continued in the study, those who initiated ADA+MTX combination therapy retained better outcomes through 10 yrs than pts who began treatment with MTX or ADA monotherapy.
Disclosure:
E. C. Keystone,
AbbVie Inc., AstraZeneca, Biotest, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche, and UCB,
5,
AbbVie Inc., Amgen, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Pfizer, Roche, and UCB,
2,
AbbVie Inc., Amgen, BMS, Janssen, Merck, Pfizer, Roche, and UCB,
8;
F. C. Breedveld,
Centocor, Schering-Plough, Amgen/Wyeth, and AbbVie Inc,
5;
D. van der Heijde,
AbbVie Inc., Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Wyeth,
5,
Imaging Rheumatology bv,
9;
R. Landewe,
AbbVie Inc., Amgen, BMS, Centocor, GSK, Merck, Novartis, Pfizer, Roche, Schering-Plough, UCB, and Wyeth,
5,
Rheumatology Consultancy bv,
4;
S. Florentinus,
AbbVie,
1,
AbbVie,
3;
U. Arulmani,
AbbVie,
1,
AbbVie,
3;
S. Liu,
AbbVie,
1,
AbbVie,
3;
H. Kupper,
AbbVie,
1,
AbbVie,
3;
A. Kavanaugh,
AbbVie Inc., Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB,
2,
AbbVie Inc., Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB,
5.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-impact-of-delaying-combination-therapy-with-adalimumab-plus-methotrexate-by-2-years-in-patients-with-early-rheumatoid-arthritis-final-10-year-results-of-the-premier-trial/